Đang chuẩn bị liên kết để tải về tài liệu:
báo cáo hóa học:" Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí sinh học quốc tế đề tài : Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer | Journal of Translational Medicine BioMed Central Open Access Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer David O Azorsa 1 Irma M Gonzales1 Gargi D Basu1 Ashish Choudhary1 Shilpi Arora1 Kristen M Bisanz1 Jeffrey A Kiefer1 Meredith C Henderson1 Jeffrey M Trent2 Daniel D Von Hoff3 and Spyro Mousses1 Address Pharmaceutical Genomics Division The Translational Genomics Research Institute Scottsdale Arizona 85259 USA 2Genetic Basis of Human Disease Division The Translational Genomics Research Institute Phoenix Arizona 85004 USA and 3Clinical Translational Research Division The Translational Genomics Research Institute Phoenix Arizona 85004 USA Email David O Azorsa - dazorsa@tgen.org Irma M Gonzales - igonzales@tgen.org Gargi D Basu - gbasu@carismpi.com Ashish Choudhary - achoudhary@tgen.org Shilpi Arora - sarora@tgen.org Kristen M Bisanz - kbisanz@tgen.org Jeffrey A Kiefer - jkiefer@tgen.org Meredith C Henderson - mhenderson@tgen.org Jeffrey M Trent - jtrent@gen.org Daniel D Von Hoff - dvh@tgen.org Spyro Mousses - smousses@tgen.org Corresponding author Published II June 2009 Journal of Translational Medicine 2009 7 43 doi I0.II 86 1479-5876-7-43 Received I2 March 2009 Accepted II June 2009 This article is available from http www.translational-medicine.cOm content 7 I 43 2009 Azorsa et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http creativecommons.org licenses by 2.0 which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Pancreatic cancer retains a poor prognosis among the gastrointestinal cancers. It affects 230 000 individuals worldwide has a very high mortality rate and remains one of the most challenging malignancies to treat successfully. Treatment with gemcitabine the most widely used chemotherapeutic against pancreatic cancer .